Damian C. Ekiert

Damian C. Ekiert

Auto-generated profile, based on publicly available information

Damian C. Ekiert

Department of Biology, Johns Hopkins University, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2009 in Science
Verified
Journal Article
Closed access
PDF file
DEDamian C. Ekiert
Damian C. Ekiert
GBGira Bhabha
Gira Bhabha
MEMarc-André Elsliger
Marc-André Elsliger
RFRobert H. E. Friesen
Robert H. E. Friesen
MJMandy Jongeneelen
Mandy Jongeneelen
IWIan A. Wilson
Ian A. Wilson
Influenza virus presents an important and persistent threat to public health worldwide, and current vaccines provide immunity to viral isolates similar to the vaccine strain. High-affinity antibodies against a conserved epitope could provide immunity to the diverse influenza subtypes and protection against future pandemic viruses. Cocrystal structures were determined at 2.2 and 2.7 angstrom resolutions for broadly neutralizing human antibody CR6261 Fab in complexes with the major surface antigen (hemagglutinin, HA) from viruses responsible for the 1918 H1N1 influenza pandemic and a recent lethal case of H5N1 avian influenza. In contrast to other structurally characterized influenza antibodies, CR6261 recognizes a highly conserved helical region in the membrane-proximal stem of HA1 and HA2. The antibody neutralizes the virus by blocking conformational rearrangements associated with membrane fusion. The CR6261 epitope identified here should accelerate the design and implementation of improved vaccines that can elicit CR6261-like antibodies, as well as antibody-based therapies for the treatment of influenza.

14 September 2012 in Science
Verified
Journal Article
Closed access
PDF file
CDCyrille Dreyfus
Cyrille Dreyfus
NLNick Stub Laursen
Nick Stub Laursen
TKTed Kwaks
Ted Kwaks
DZDavid Zuijdgeest
David Zuijdgeest
RKReza Khayat
Reza Khayat
RFRobert H. E. Friesen
Robert H. E. Friesen
Influenza Antibodies, Part B: With its ability to reassort in animal hosts like pigs and birds, and to cause pandemics, influenza A viruses are often in the spotlight. However, a substantial portion of the annual flu burden is also the result of influenza B virus, which is a single influenza type that is characterized by two antigenically and genetically distinct lineages. Dreyfus et al. (p. 1343 , published online 9 August) identify three monoclonal human antibodies that are able to protect against lethal infection with both lineages of influenza B virus in mice. Two antibodies, which bind to distinct regions of the viral hemagluttinin (HA) molecule, neutralize multiple strains from both lineages of influenza B virus, whereas the third antibody binds to the stem region of HA and is able to neutralize both influenza A and B strains. The structural data from these antibodies bound to HA, together with already known antibodies targeting influenza A, may provide clues for designing a universal vaccine to protect against both influenza virus types.

12 August 2011 in Science
Verified
Journal Article
Closed access
PDF file
DEDamian C. Ekiert
Damian C. Ekiert
RFRobert H. E. Friesen
Robert H. E. Friesen
GBGira Bhabha
Gira Bhabha
TKTed Kwaks
Ted Kwaks
MJMandy Jongeneelen
Mandy Jongeneelen
JGJaap Goudsmit
Jaap Goudsmit
Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of VH1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.

13 May 2011 in Science
Verified
Journal Article
Closed access
PDF file
SFSarel Fleishman
Sarel Fleishman
TWTimothy A. Whitehead
Timothy A. Whitehead
DEDamian C. Ekiert
Damian C. Ekiert
CDCyrille Dreyfus
Cyrille Dreyfus
JCJacob E. Corn
Jacob E. Corn
DBDavid Baker
David Baker
Proteins can be designed that bind to specific patches on target proteins to alter their subsequent interactions.

16 April 2010 in Science
Verified
Journal Article
Closed access
PDF file
RXRui Xu
Rui Xu
DEDamian C. Ekiert
Damian C. Ekiert
JKJens C. Krause
Jens C. Krause
RHRong Hai
Rong Hai
JCJames E. Crowe
James E. Crowe
IWIan A. Wilson
Ian A. Wilson
Swine Flu Neutralized: The 2009 H1N1 flu virus had an unusually low infection rate in elderly people. An antibody isolated from survivors of the 1918 flu pandemic was recently shown to cross-neutralize 2009 H1N1 viruses. Xu et al. (p. 357 , published online 25 March) report crystal structures of the virus envelope protein, hemagglutinin (HA) from 2009 H1N1 and of 1918 H1 HA in complex with a neutralizing antibody that cross-reacts with both pandemic viruses. These studies reveal an epitope that is conserved in the pandemic viruses, but divergent in other known H1 HAs, from the 1930s to the present. This antigenic similarity explains the age-related immunity to the 2009 H1N1 influenza.

16 September 2012 in Nature
Verified
Journal Article
Closed access
PDF file
DEDamian C. Ekiert
Damian C. Ekiert
AKArun K. Kashyap
Arun K. Kashyap
JSJohn Steel
John Steel
ARAdam Rubrum
Adam Rubrum
GBGira Bhabha
Gira Bhabha
IWIan A. Wilson
Ian A. Wilson